Nifuroxazide Lavipharm (Nifuroxazide)

Nifuroxazide penetrates bacterial cells in the gastrointestinal tract and is reduced to reactive nitro‑radical species. These intermediates damage bacterial DNA, inhibit protein synthesis and interfere with key metabolic enzymes, resulting in a bacteriostatic effect against a range of Gram‑positive and Gram‑negative bacteria.

The dosage of Nifuroxazide Lavipharm is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of infection and local treatment guidelines. Patients should follow the prescriber’s instructions and the information provided on the product label.

Safety data for nifuroxazide in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike symptomatic agents such as loperamide, nifuroxazide has antibacterial activity that targets the underlying bacterial cause of diarrhea. It is comparable to other nitrofuran antibiotics but differs from broad‑spectrum agents by remaining largely confined to the intestinal lumen, which reduces systemic exposure.

The product should be stored at room temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the tablets away from children and do not use after the expiry date printed on the label.

Nifuroxazide Lavipharm is taken orally, usually with a glass of water. The tablets should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional. Administration is typically after meals to reduce gastrointestinal irritation.

The most serious adverse reactions include severe allergic responses such as anaphylaxis, rare skin disorders like Stevens‑Johnson syndrome or toxic epidermal necrolysis, significant liver enzyme elevations indicating hepatotoxicity, and the potential for Clostridioides difficile‑associated colitis.

Individuals with a known hypersensitivity to nifuroxazide or other nitrofuran compounds should avoid the medication. It is also contraindicated in patients with viral gastroenteritis, and caution is advised in those with severe hepatic or renal impairment, unless a prescriber determines that benefits outweigh risks.